IPO - CapsoVision, Inc

Form Type: 424B4

Filing Date: 2025-07-03

Corporate Action: Ipo

Type: New

Accession Number: 000119312525155088

Filing Summary: CapsoVision, Inc. is conducting its initial public offering (IPO) by offering 5,500,000 shares of common stock at an initial price of $5.00 per share. The offering aims to raise approximately $27.5 million, with underwriting discounts and commissions planned to total around $1.93 million. Existing stockholders and additional investors have agreed to purchase approximately $18.9 million in shares, representing about 69% of the shares being sold in this IPO. CapsoVision's common stock has received approval for listing on the Nasdaq Capital Market under the symbol 'CV'. The company qualifies as an 'emerging growth company' and is subject to reduced public company reporting requirements, thereby presenting a potential risk for investors. This offering is viewed as a high-risk investment opportunity, primarily for individuals who can afford to lose their entire investment. The expected closing and delivery of shares to investors are set for July 3, 2025. The funds raised will support the commercialization of CapsoVision’s products, including the CapsoCam systems and further development of their AI technology for medical imaging, particularly in gastrointestinal diagnostics, which remains a focus for future revenue growth.

Form Type: 8-K

Filing Date: 2025-07-03

Corporate Action: Ipo

Type: New

Accession Number: 000119312525155527

Filing Summary: On July 1, 2025, CapsoVision, Inc. entered into an underwriting agreement with The Benchmark Company, LLC and Roth Capital Partners, LLC for the issuance of 5,500,000 shares of its common stock at $5.00 per share in its initial public offering (IPO). The offering closed on July 3, 2025, resulting in gross proceeds of $27.5 million. The underwriters were granted a 30-day overallotment option for up to 825,000 additional shares and were issued warrants for 165,000 shares of common stock. The IPO was registered under file number 333-287148 and resulted in CapsoVision's stock being approved for listing on The Nasdaq Capital Market under the symbol 'CV' as of July 2, 2025. Additionally, the Company amended its certificate of incorporation and bylaws in relation to the IPO, which became effective on the closing date.

Form Type: S-1/A

Filing Date: 2025-06-27

Corporate Action: Ipo

Type: New

Accession Number: 000119312525149285

Filing Summary: CapsoVision, Inc. is conducting an initial public offering (IPO) to sell 5,250,000 shares of its common stock, with an estimated price range of $5.00 to $5.50 per share. This IPO is part of their registration statement under the Securities Act of 1933, specifically Amendment No. 3 to Form S-1. CapsoVision is a commercial-stage medical technology company that specializes in advanced imaging and AI technologies for capsule endoscopy, aimed at diagnosing gastrointestinal (GI) tract abnormalities. The company has developed the CapsoCam Plus capsule endoscope system and plans to enhance its capabilities with AI-assisted features. The proposed offering has generated significant interest with indications amounting to approximately $19.4 million from both existing stockholders and new potential investors. CapsoVision is targeting the listing of its common stock on the Nasdaq under the symbol 'CV'. The company classifies itself as an emerging growth and smaller reporting company, which permits it to enjoy reduced reporting requirements. Additionally, the document mentions plans for future expansions into new markets and product offerings. It highlights a history of revenue growth and outlines risks associated with the FDA approval processes, market competition, and the necessity for ongoing funding to support growth strategies. Overall, the IPO will facilitate the company's growth by increasing capital for product development and market expansion.

Form Type: 8-A12B

Filing Date: 2025-06-13

Corporate Action: Ipo

Type: New

Accession Number: 000119312525140839

Filing Summary: CapsoVision, Inc. has filed Form 8-A for the registration of its common stock, with a par value of $0.001 per share, to be traded on The Nasdaq Stock Market LLC. The registration is part of the company's ongoing initial public offering process, reflected in the related Registration Statement on Form S-1, filed initially on May 9, 2025. This filing confirms that the common stock will be registered under Section 12(b) of the Securities Exchange Act of 1934, with no other securities registered concurrently. The filing was signed by the Chief Financial Officer, Kevin Lundquist, on June 13, 2025.

Form Type: S-1/A

Filing Date: 2025-06-13

Corporate Action: Ipo

Type: New

Accession Number: 000119312525140836

Filing Summary: CapsoVision, Inc. is conducting an initial public offering (IPO) of its common stock, with the offering consisting of 5,250,000 shares priced between $5.00 and $5.50 per share. This follows indications of interest totaling approximately $19.2 million from existing stockholders and potential investors, representing about 70% of the shares to be sold at a midpoint price of $5.25. The company plans to list its stock on the Nasdaq under the symbol 'CV' and expects to deliver shares to investors on a date to be announced in 2025. The registration statement has not yet become effective, and the preliminary prospectus indicates that CapsoVision is an emerging growth company, facing risks related to financial performance, market acceptance of its products, and competition. In 2023 and 2024, the company has reported revenue growth driven primarily by the sales of its CapsoCam Plus capsule endoscope system, with plans to develop additional products and leverage advancements in artificial intelligence to enhance its offerings. A reverse stock split is also planned to ensure a proper capital structure before the IPO takes place.

Form Type: S-1/A

Filing Date: 2025-05-30

Corporate Action: Ipo

Type: New

Accession Number: 000119312525132293

Filing Summary: This document is the first amendment to the Form S-1 registration statement for CapsoVision, Inc., filed for their initial public offering (IPO). CapsoVision, a Delaware-based company, develops advanced capsule endoscopy technologies aimed at diagnosing and screening gastrointestinal (GI) tract abnormalities. The offering consists of 5,250,000 shares of common stock, with an anticipated initial offering price between $5.00 and $5.50 per share, and is seeking to list on the Nasdaq Capital Market under the symbol 'CV'. The prospectus outlines the emerging growth company status of the firm, reflecting reduced regulatory requirements. The company has experienced revenue growth, with approximately $9.8 million in 2023 and $11.8 million in 2024, mainly from CapsoCam Plus sales. Future plans include launching a new product, the CapsoCam Colon, with expected revenue commencing in 2026. The document emphasizes the high-risk nature of investing, citing the speculative nature of the offering and uncertainties regarding FDA approvals and market competition.

Form Type: S-1

Filing Date: 2025-05-09

Corporate Action: Ipo

Type: New

Accession Number: 000119312525116894

Filing Summary: CapsoVision, Inc. is filing for an initial public offering (IPO) of common stock, intending to offer shares in a range between a specified price per share, with the exact amount to be determined later. As an emerging growth and smaller reporting company, CapsoVision anticipates a public market establishment for its shares following the completion of the registration statement with the SEC. The company's products, including the CapsoCam Plus and upcoming CapsoCam Colon, are focused on enhancing gastrointestinal (GI) diagnostic capabilities through advanced imaging technology and artificial intelligence. Their business aims to improve the detection of small bowel abnormalities and colorectal polyps, which are critical for preventing more serious health conditions. The preliminary prospectus indicates that there is significant market potential, especially within the capsule endoscopy market, which is projected to grow significantly by 2030. The company highlights its commitment to innovation, regulatory compliance, and evolving their product offerings while also indicating risk factors tied to its growth and market competition.

Form Type: DRS/A

Filing Date: 2025-03-14

Corporate Action: Ipo

Type: New

Accession Number: 000095012325003072

Filing Summary: CapsoVision, Inc. is preparing for its initial public offering (IPO) by filing a registration statement with the SEC. This document details the offering of shares of common stock valued at $0.001 per share, with the initial public offering price expected to range between an unlisted minimum and maximum amount. The registration indicates that there has been no public market for the company's shares prior to this offering. CapsoVision, based in Saratoga, CA, focuses on advanced imaging and AI technologies for gastrointestinal applications, primarily through its CapsoCam Plus product. The company targets the U.S. market for its capsule endoscopy and anticipates substantial growth driven by increasing adoption of its products in gastroenterology. The SEC filing states that CapsoVision qualifies as an emerging growth and smaller reporting company, allowing it to take advantage of reduced disclosure and reporting obligations. Furthermore, the prospectus includes a warning about the speculative nature of the investment due to the inherent risks in the market and technology sector they operate in.

Form Type: DRS

Filing Date: 2025-02-07

Corporate Action: Ipo

Type: New

Accession Number: 000095012325001205

Filing Summary: CapsoVision, Inc. is filing a draft registration statement with the SEC for an initial public offering (IPO) of common stock. This is the first public offering of CapsoVision's common stock, where they plan to offer shares at a price range yet to be defined. The common stock will be listed on the Nasdaq under the symbol 'CV'. CapsoVision specializes in advanced imaging and AI technologies related to capsule endoscopy for gastrointestinal diagnostics. They are currently an emerging growth company and have seen continuous revenue growth since establishing direct sales in the U.S. since 2020, with revenues for the years ending December 31, 2023, and 2024 reported at approximately $9.8 million, reflecting market expansion and product acceptance. They emphasize the high speculative nature of the investment due to market risks, the need for FDA clearances for future products, and the uncertainties involved in forward-looking statements about operational and financial performance.